PVIVAX Knowledge sharing for relapsing malaria
P. vivax malaria studies: A database of studies focusing on improving access to radical cure.
About the P. vivax information hub.
PAVE is conducting feasibility studies and operational research to support Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals.
The Brazilian Ministry of Health (MoH) and MMV, are conducting a study to understand the feasibility of providing appropriate radical cure treatment (primaquine - PQ - or tafenoquine – TQ) based on the results of G6PD testing conducted in real-world settings.
This short film introduces the 'ARCTIC' feasibility study in Thailand. A study looking at the operational feasibility of using quantitative G6PD testing prior to treatment for Plasmodium vivax malaria relapse with tafenoquine or primaquine.
This short video explores the role of the APMEN Vivax Working Group in the fight against malaria in the Asia-Pacific region. The APMEN Vivax Working Group is currently hosted and co-chaired by Medicines for Malaria Venture (MMV).
Plasmodium vivax cases represent more than 50% of a diminishing malaria case load in Vietnam. Safe and effective radical cure strategies could support malaria elimination by 2030. This study investigated the operational feasibility of introducing point-of-care quantitative glucose-6-phosphate dehydrogenase (G6PD) testing into malaria case management practices.
This paper outlines the process of OAT development in detail to inform relevant stakeholders and assist other researchers developing similar toolkit/s in other settings for malaria or for other diseases.
This study aims to analyse the association of G6PDd and anaemia in malaria patients receiving anti-malarial drugs.